CAS 2381089-83-2 · MW 4731.33. Novel triple-receptor agonist (EC₅₀: GLP-1R 0.775 nM, GIPR 0.064 nM, GCGR 5.79 nM). Phase 2: 15–24% mean weight reduction — the highest published for any GLP-1-class compound. GCGR activation drives direct fat oxidation and thermogenesis absent from all single and dual agonists. Zero androgenic effects — fully applicable to female biology research.
Retatrutide 10mg | 10-Vial Kit 10mg/vial · 100mg total
CAS 70-18-8 · MW 307.32. γ-Glu-Cys-Gly — primary intracellular antioxidant. Dual relevance to Venus Protocol: (1) Tyrosinase inhibition — reduces melanin synthesis, shifts production toward lighter pheomelanin for skin brightening and tone evenness; (2) Hepatoprotection and Phase II conjugation — supports detoxification during multi-compound research protocols. Paired with GHK-Cu for comprehensive skin research coverage.
Glutathione 600mg | 10-Vial Kit 600mg/vial · 6000mg total
CAS 137525-51-0 · MW 1419.53. Stable 15-AA gastric pentadecapeptide. Modulates NO pathways, EGF/FGF/VEGF growth factor signaling, and FAK-paxillin integrin cascades. IBS affects women at 1.5–3× the rate of men — BPC-157’s gut barrier repair, motility modulation, and anti-inflammatory research is therefore proportionally more relevant to female biology. Also researched for tendon/ligament healing and neuroprotection.
BPC-157 10mg | 10-Vial Kit 10mg/vial · 100mg total
CAS 32780-32-8 · MW 1025.18. MC4R agonist in the CNS — medial preoptic area and ventromedial hypothalamus (desire/motivation pathways). FDA acknowledgment as Vyleesi for HSDD in premenopausal women — the only non-hormonal compound with this clinical designation. RECONNECT Phase 3 programme: 1,200+ women, demonstrated significant increase in satisfying sexual events vs placebo. No estrogen, progesterone, or testosterone manipulation. No androgenic effects.
CAS 307297-39-8 · MW 390.35. Ala-Glu-Asp-Gly — synthetic tetrapeptide based on pineal gland epithalamin. Primary mechanism: telomerase activation. Telomeres — the protective caps on chromosome ends — shorten with each cell division; critically short telomeres trigger cellular senescence or apoptosis. Research goal: maintaining telomere length to extend functional cellular lifespan. Also researched for melatonin normalisation (particularly relevant post-menopause) and antioxidant enzyme upregulation.
Epithalon 10mg | 10-Vial Kit 10mg/vial · 100mg total
CAS 863288-34-0 · MW 3367.97. Modified GRF 1-29 — GHRH receptor agonist at anterior pituitary. Half-life ~30 min producing pulsatile GH release matching natural rhythms. Selected over CJC With DAC specifically for the Venus Protocol because pulsatile GH (not continuous) is the appropriate pattern for sleep quality and skin elasticity research. Does not cause receptor desensitisation at physiological pulse frequencies.
CJC-1295 No DAC 5mg | 10-Vial Kit 5mg/vial · 50mg total
CAS 170851-70-4 · MW 711.85. Pentapeptide GHSR-1a agonist. Highest receptor selectivity of any ghrelin mimetic. Critically for Venus Protocol: stimulates GH release without raising cortisol, prolactin, or aldosterone — side effects present with GHRP-2, GHRP-6, and Hexarelin. Combined with CJC-1295 No DAC, creates synergistic GH pulses researched for improved sleep architecture, skin elasticity, fat-to-lean body composition, and recovery.
Ipamorelin 5mg | 10-Vial Kit 5mg/vial · 50mg total
Why does the Venus Protocol use Retatrutide instead of Semaglutide?
Retatrutide adds GCGR agonism to GLP-1R + GIPR — the glucagon receptor component drives direct hepatic fat oxidation and thermogenesis that semaglutide’s single GLP-1R agonism cannot achieve. Phase 2 data showed ~24% mean weight reduction for Retatrutide vs ~14.9% for semaglutide alone. Retatrutide has no androgenic effects, making it equally applicable to women’s health research.
What is the Epithalon + NAD+ anti-aging rationale?
NAD+ addresses mitochondrial dysfunction — the primary cellular energy deficit associated with ageing. Epithalon addresses telomere shortening — the chromosomal integrity mechanism of cellular ageing. Together they provide dual-mechanism anti-aging coverage: metabolic function (NAD+) and genomic stability (Epithalon). Research suggests these mechanisms are complementary rather than redundant.
Why is Glutathione particularly relevant for skin research in women?
Glutathione inhibits tyrosinase, the key enzyme in melanin synthesis, shifting production from eumelanin (darker) toward pheomelanin (lighter/rosier). Multiple clinical studies have examined injectable Glutathione specifically for skin brightening and pigmentation. Paired with GHK-Cu’s collagen activation, these two compounds address the full spectrum of skin quality research: structural integrity (GHK-Cu) and tone/brightness (Glutathione).
What is the RECONNECT clinical programme for PT-141?
RECONNECT was a Phase 3 clinical programme evaluating Bremelanotide (PT-141) specifically for hypoactive sexual desire disorder (HSDD) in premenopausal women. The programme involved over 1,200 women and provided the data for the FDA’s acknowledgment of Bremelanotide as Vyleesi. PT-141 is the only non-hormonal, CNS-mediated compound with this level of clinical validation for female sexual desire research.
Why is Ipamorelin preferred over GHRP-2 or GHRP-6 for women’s health research?
GHRP-2 and GHRP-6 both elevate cortisol and prolactin in addition to stimulating GH. For women’s health research, cortisol elevation (catabolic, sleep-disrupting) and prolactin elevation (hormonal interference) are undesirable. Ipamorelin is the only GH secretagogue that does not raise cortisol or prolactin at research doses — making it uniquely suited for the Venus Protocol’s clean hormonal profile requirement.
